Population-Level Effectiveness and Herd Protection 17 Years After HPV Vaccine Introduction

Posted September 25, 2025 by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, SEPTEMBER 29, 2025

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2025.3568?guestAccessKey=1f5330ce-e0df-4b35-9f69-dd10a6fdb61d&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092925

About The Study: In this study, population-level effectiveness and herd protection were robust 17 years after human papillomavirus (HPV) vaccine introduction, even in sexually experienced adolescent girls and young women at relatively high risk for HPV who may not have received the full vaccination series.

Corresponding Author: To contact the corresponding author, Jessica Kahn, MD, MPH, email jessica.kahn@einsteinmed.edu.

(doi:10.1001/jamapediatrics.2025.3568)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Modeling the Health Impact of Discontinuing COVID-19 Vaccination During Pregnancy in the US

Posted September 25, 2025 by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, SEPTEMBER 29, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2025.3561?guestAccessKey=19e51868-8c00-4bc4-8bff-4c5590049a75&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092925

About The Study: This decision analytical model study estimates that COVID-19 vaccination (primarily annual COVID-19 vaccination) during pregnancy will likely continue to yield meaningful public health benefits in the U.S., especially to reduce COVID-19 hospitalizations in infants. COVID-19 vaccination during pregnancy has been shown to be safe. While there is global variation in policy recommending COVID-19 vaccination during pregnancy, the U.S. has a high risk of severe COVID-19 in newborns, underscoring relevance of maternal COVID-19 vaccination.

Corresponding Author: To contact the corresponding author, Nathan C. Lo, MD, PhD, email nathan.lo@stanford.edu.

(doi:10.1001/jamapediatrics.2025.3561)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

The Rise in Early-Onset Cancer in the US Population— More Apparent Than Real

Posted September 25, 2025 by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, SEPTEMBER 29, 2025

Media advisory: The full study and editor’s note are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2025.4917?guestAccessKey=fff8b54b-04ee-4400-b341-d8b61531cc46&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092925

About The Study: The rise in early-onset cancer incidence does not consistently signal a rise in the occurrence of clinically meaningful cancer. While some of the increase in early-onset cancer is likely clinically meaningful, it appears small and limited to a few cancer sites. Much of the increase appears to reflect increased diagnostic scrutiny and over-diagnosis. Interpreting rising incidence as an epidemic of disease may lead to unnecessary screening and treatment while also diverting attention from other more pressing health threats in young adults.

Corresponding Author: To contact the corresponding author, H. Gilbert Welch, MD, MPH, email drgilwelch@gmail.com.

(doi:10.1001/jamainternmed.2025.4917)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene Therapies

Posted September 24, 2025 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11:00 A.M. ET, MONDAY, SEPTEMBER 29, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.15148?guestAccessKey=ec35a0f8-f298-4c4b-b6b6-080a7ea92448&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092925

About The Study: For Food and Drug Administration (FDA)-approved cell and gene therapies, commercial health plans commonly imposed coverage requirements beyond FDA-approved product labeling. These restrictions were often aligned with pivotal trial criteria, suggesting that plan coverage aligns with stronger supporting evidence.

Corresponding Author: To contact the corresponding author, James D. Chambers, PhD, email james.chambers@tuftsmedicine.org.

(doi:10.1001/jama.2025.15148)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Benefit-Risk Reporting for FDA-Cleared AI−Enabled Medical Devices

Posted September 24, 2025 by Jim Michalski

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, SEPTEMBER 26, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2025.3351?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=092625

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

About The Study: This cross-sectional study suggests that despite increasing clearance of artificial intelligence (AI)/machine learning (ML) devices, standardized efficacy, safety, and risk assessment by the Food and Drug Administration (FDA) are lacking. Dedicated regulatory pathways and post-market surveillance of AI/ML safety events may address these challenges.

Corresponding Author: To contact the corresponding author, Ravi B. Parikh, MD, MPP, email ravi.bharat.parikh@emory.edu.

(doi:10.1001/jamahealthforum.2025.3351)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Racial and Ethnic Disparities in Occupational Health

Posted September 24, 2025 by Jim Michalski

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, SEPTEMBER 26, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2025.3495?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=092625

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

About The Study: Disparities in workplace safety are a significant contributor to racial and ethnic health disparities. Addressing both occupational concentration and within-occupation disparities is essential for improving workplace safety and reducing health inequities among workers.

Corresponding Author: To contact the corresponding author, Michael Dworsky, PhD, email mdworsky@rand.org.

(doi:10.1001/jamahealthforum.2025.3495)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Child and Adolescent Firearm-Related Homicide Occurring at Home

Posted September 24, 2025 by Jim Michalski

JAMA Surgery

EMBARGOED FOR RELEASE: 10:50 A.M. (ET), FRIDAY, SEPTEMBER 26, 2025

Media advisory: The full study and commentary are linked to this news release. This study is being presented at the American Academy of Pediatrics 2025 National Conference & Exhibition.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2025.3429?guestAccessKey=2a034b8d-1437-46a2-8f3c-fdfe2b414d7b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092625

About The Study: This study found that nearly one-quarter of pediatric firearm-related homicides occurred at home. Young children were more often affected. These data point to domestic violence and child abuse as significant risk factors for in-home firearm homicide. Traditional safe storage laws may be inadequate preventive measures. Extreme risk protection orders and mandatory domestic violence–related firearm relinquishment may prevent these deaths and warrant further investigation.

Corresponding Author: To contact the corresponding author, Jordan M. Rook, MD, email jrook@mednet.ucla.edu.

(doi:10.1001/jamasurg.2025.3429)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

600- vs 400-mg First-Line Ribociclib in Hormone Receptor–Positive/ ERBB2-Negative Advanced Breast Cancer

Posted September 23, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.3687?guestAccessKey=74e33a77-e26e-438e-bf01-504773a8f985&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092525

Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2-Negative Early Breast Cancer

Posted September 23, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.3700?guestAccessKey=267e72e4-4973-466b-a10a-967daf517798&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092525

School Provision of Universal Free Meals and Blood Pressure Outcomes Among Youths

Posted September 23, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, SEPTEMBER 25, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.33186?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092525

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This cohort study of schools matched to child and adolescent patient medical records from a large network of community health organizations found that school participation in the Community Eligibility Provision was associated with a net reduction in blood pressure outcomes. These findings add to mounting evidence that universal free school meals may be associated with improved child health.

Corresponding Author: To contact the corresponding author, Anna M. Localio, PhD, MPH, email alocalio@uw.edu.

(doi:10.1001/jamanetworkopen.2025.33186)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Olfactory Dysfunction After SARS-CoV-2 Infection

Posted September 23, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, SEPTEMBER 25, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.33815?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092525

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This cohort study examines the presence, severity, and patterns of olfactory dysfunction in U.S. adults with and without prior SARS-CoV-2 infection.

Corresponding Author: To contact the corresponding author, Leora I. Horwitz, MD, MHS, email Leora.horwitz@nyulangone.org.

(doi:10.1001/jamanetworkopen.2025.33815)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Low-Dose Aspirin for Individualized Cancer Prevention in Older Adults

Posted September 23, 2025 by Jim Michalski

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, SEPTEMBER 25, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.3593?guestAccessKey=d6830a98-4415-4b34-a5b9-e92552142e7c&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092525

About The Study: The findings of this analysis suggest that the individualized treatment effect of low-dose aspirin on cancer prevention in older adults varies by participant characteristics. Further study is needed to fully understand the implications of these findings.

Corresponding Author: To contact the corresponding author, Le Thi Phuong Thao, PhD, email thao.le@monash.edu.

(doi:10.1001/jamaoncol.2025.3593)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Hospital Price Markup and Outcomes of Major Elective Operations

Posted September 22, 2025 by Jim Michalski

JAMA Surgery

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, SEPTEMBER 24, 2025

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2025.3647?guestAccessKey=6b8c55f5-7996-49ee-9a2b-386b6af37c42&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092425

About The Study: This cross-sectional study found that considerable variation in price markup exists across hospitals and that high-markup hospitals demonstrated both lower quality and value of care. These findings underscore that high-markup hospitals represent a key initial target for national policy efforts targeting pricing regulation, transparency, and quality improvement.

Corresponding Author: To contact the corresponding author, Peyman Benharash, MD, email pbenharash@mednet.ucla.edu.

(doi:10.1001/jamasurg.2025.3647)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Discontinuation of Semaglutide Among Older Adults With Diabetes in the US and Japan

Posted September 22, 2025 by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, SEPTEMBER 24, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.3109?guestAccessKey=28d146b1-0d26-4c68-959a-d0f87f734531&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092425

About The Study: In this binational study of older adults with diabetes, nearly 6 in 10 U.S. adults and 3 in 10 Japanese adults discontinued glucagon-like peptide-1 receptor agonists (GLP-1RAs) within 12 months of initiating injectable semaglutide. Patients with established cardiovascular disease and chronic kidney disease had higher discontinuation rates in both countries, which is troublesome given the substantial clinical benefit these high-risk individuals would be expected to derive from GLP-1RA therapy.

Corresponding Author: To contact the corresponding author, Dhruv S. Kazi, MD, MSc, MS, email dkazi@bidmc.harvard.edu.

(doi:10.1001/jamacardio.2025.3109)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Measles Vaccination Coverage After a Post-Elimination Outbreak

Posted September 22, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, SEPTEMBER 24, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.33732?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092425

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this repeated cross-sectional study of 149,000 children in a large central Ohio primary care network during the 20 months after outbreak onset, all measures of measles-mumps-rubella (MMR) coverage remained well below the 93% herd immunity threshold. These persistent, population-wide immunity gaps suggest the need for sustained, equity-focused public health strategies to maintain measles elimination.

Corresponding Author: To contact the corresponding author, Rosemary A. Martoma, MD, MBChB, email rose@kidsmates.org.

(doi:10.1001/jamanetworkopen.2025.33732)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists

Posted September 19, 2025 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11:00 A.M. ET, WEDNESDAY, SEPTEMBER 24, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.15841?guestAccessKey=90ed03f8-3941-432a-93c7-40f38610b943&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092425

About The Study: From 2020 to 2025, prior authorization for glucagon-like peptide-1 receptor agonists (GLP-1RAs) became near universal and out-of-pocket costs rose substantially in 2025, as plans increasingly required coinsurance. Although the rise in prior authorization may reflect efforts to curtail off-label GLP-1RA use, recent increases in out-of-pocket costs likely resulted from broader shifts to coinsurance affecting many high-cost drugs.

Corresponding Author: To contact the corresponding author, Matthew J. Klebanoff, MD, MSHP, email matthew.klebanoff@pennmedicine.upenn.edu.

(doi:10.1001/jama.2025.15841)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Insurance Dynamics During Childhood in the Fragmented US Health System

Posted September 19, 2025 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11:00 A.M. ET, WEDNESDAY, SEPTEMBER 24, 2025

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.15488?guestAccessKey=5a9c54d2-44b1-42cc-9605-7d82dab82020&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092425

About The Study: An estimated 3 of 4 U.S. children relied on publicly subsidized insurance (Medicaid, Children’s Health Insurance Program [CHIP], or Marketplace) or experienced a period without any insurance by their 18th birthday in the post-Affordable Care Act (ACA), pre-pandemic policy environment. Substantial state heterogeneity in childhood un-insurance underscores the critical role of Medicaid policies.

Corresponding Author: To contact the corresponding author, Ye Shen, MSPH, email ye_shen@fas.harvard.edu.

(doi:10.1001/jama.2025.15488)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Health Care Affordability Problems by Income Level and Subsidy Eligibility in Medicare

Posted September 18, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32862?guestAccessKey=e671de0f-26b4-4fef-bda8-1fddf364df86&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092225

Cognitive Behavioral Therapy for Insomnia in People With Chronic Disease

Posted September 18, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2025.4610?guestAccessKey=7689281a-f68e-4694-bbe5-b34eb9d173fd&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092225

Long-Term Personalized Adaptive Deep Brain Stimulation in Parkinson Disease

Posted September 18, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2025.2781?guestAccessKey=43e3b5b8-fc57-4eee-a6e6-2479cbec22da&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092225

Adaptive vs Monthly Support for Weight-Loss Maintenance

Posted September 18, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32681?guestAccessKey=455fedc4-ca12-45ba-a810-93d3c3ff3775&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092225

Label Statements and Perceived Health Benefits of Dietary Supplements

Posted September 18, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.33118?guestAccessKey=5404d05a-53e6-45ab-b37f-b4e04f53d209&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092225

Alcohol Consumption Per Capita and Suicide

Posted September 18, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, SEPTEMBER 22, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.33129?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092225

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this systematic review and meta-analysis, an increase in alcohol consumption per capita was associated with an increase in the suicide mortality rate at the population level and that the association was similar across sexes. As such, alcohol consumption per capita may be a useful target to consider within comprehensive national suicide prevention strategies.

Corresponding Author: To contact the corresponding author, Shannon Lange, PhD, email shannon.lange@camh.ca.

(doi:10.1001/jamanetworkopen.2025.33129)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Prevalence and Trajectories of Perinatal Anxiety and Depression in a Large Urban Medical Center

Posted September 18, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, SEPTEMBER 22, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.33111?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092225

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: The findings of this study underscore the need for routine and consistent screening, monitoring, and treatment of perinatal depression and anxiety. Women who received mental health services had faster reductions in depression over time, highlighting the potential impact for scalable and efficacious interventions during this critical period.

Corresponding Author: To contact the corresponding author, Nili Solomonov, PhD, email nis2051@med.cornell.edu.

(doi:10.1001/jamanetworkopen.2025.33111)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Poverty and Social Disadvantage in Women and Men and Fertility Outcomes

Posted September 17, 2025 by Alexandra Marusarz

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, SEPTEMBER 19, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32741?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091925

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: The findings of this cohort study suggest that poverty and social disadvantage, characterized by low educational level and household income among both women and men, were associated with lower fecundability (defined as the per-month probability of conceiving) and increased risks of subfertility (defined as a time to pregnancy or the duration of actively pursuing pregnancy of more than 12 months or use of assisted reproductive technology) but not with miscarriage risk. Further studies are needed to identify the underlying and explanatory mechanisms associated with fertility outcomes and the potential for novel public health strategies for couples desiring pregnancy.

Corresponding author: To contact the corresponding author, Vincent W. V. Jaddoe, M.D., Ph.D., email v.jaddoe@erasmusmc.nl.

(doi: 10.1001/jamanetworkopen.2025.32741)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Modeling the Impact of MMR Vaccination Strategies on Measles Outbreaks in Texas

Posted September 17, 2025 by Alexandra Marusarz

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, SEPTEMBER 19, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2025.3992?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091925

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

About The Study: The findings of this study highlight the critical role of improving measles, mumps, rubella (MMR) vaccination coverage to prevent large-scale measles outbreaks, particularly in regions with declining immunization rates.

Corresponding Author: To contact the corresponding author, Kaiming Bi, Ph.D., email kaiming.bi@uth.tmc.edu.

(doi: 10.1001/jamahealthforum.2025.3992)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Child Opportunity Index and Access to Firearms Among Adolescents and Young Adults

Posted September 17, 2025 by Alexandra Marusarz

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2025.3910?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091925

Health Insurance Coverage Among Same-Sex vs Different-Sex Couples

Posted September 17, 2025 by Alexandra Marusarz

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32844?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091925

A Call to Center Latino Members of Sexual Minority Groups and Strengthen the US HIV Response

Posted September 17, 2025 by Alexandra Marusarz

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2025.3234?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091925

Stimulant Overdose Prediction Model for Medicaid-Insured Persons

Posted September 17, 2025 by Alexandra Marusarz

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2025.3489?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091925

Payments to Health Care Professionals and Teaching Hospitals by AI- and Machine Learning–Enabled Medical Device Manufacturers

Posted September 17, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.14813?guestAccessKey=038afaed-bd7d-4f2e-83eb-233502a8ef15&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=092225

Scenario Projections of COVID-19 Burden in the US, 2024-2025

Posted September 16, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, SEPTEMBER 18, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32469?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091825

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this decision analytical modeling study of COVID-19 burden in the U.S. in 2024 to 2025, ensemble projections suggested that although vaccinating high-risk groups had substantial benefits in reducing disease burden, maintaining the vaccine recommendation for all individuals had the potential to save thousands more lives. Despite divergence of projections from observed disease trends in 2024 to 2025—possibly driven by variant emergence patterns and immune escape—averted COVID-19 burden due to vaccination was robust across immune escape scenarios, emphasizing the substantial benefit of broader vaccine availability for all individuals.

Corresponding Author: To contact the corresponding author, Sung-mok Jung, PhD, email sungmok@ad.unc.edu.

(doi:10.1001/jamanetworkopen.2025.32469)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

“15% of Searches Have Never Been Typed Before”

Posted September 16, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.14860?guestAccessKey=4fcd9fbb-a901-4c24-9bd3-33fcf0aca733&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091825

Disparities by Race and Ethnicity in Percutaneous Coronary Intervention

Posted September 16, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, SEPTEMBER 18, 2025

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32660?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091825

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cross-sectional study examining racial and ethnic disparities in receipt of percutaneous coronary intervention (PCI) for patients with ST-segment elevation myocardial infarction (STEMI), racial and ethnic disparities persisted throughout the care process. The largest magnitude of disparity was PCI receipt if transferred, but the disparity with the largest impact was PCI receipt when initially presenting to PCI-capable hospitals.

Corresponding Author: To contact the corresponding author, Charleen Hsuan, JD, PhD, email chsuan@psu.edu.

(doi:10.1001/jamanetworkopen.2025.32660)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer

Posted September 16, 2025 by Jim Michalski

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, SEPTEMBER 18, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.3377?guestAccessKey=c9b60472-cdd3-4fe3-b05b-d4f24722e2ab&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091825

About The Study: In this cohort study, oral bacteria and fungi were significant risk factors for pancreatic cancer development. Oral microbiota hold promise as biomarkers to identify individuals at high risk of pancreatic cancer, potentially contributing to personalized prevention.

Corresponding Authors: To contact the corresponding authors, email Jiyoung Ahn, PhD (jiyoung.ahn@nyulangone.org) and Richard B. Hayes, DDS, PhD (richard.b.hayes@nyulangone.org).

(doi:10.1001/jamaoncol.2025.3377)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Smartphone-Based Measures as Indicators of Functional Status in Patients With Advanced Cancer

Posted September 16, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32488?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091825

Gender-Affirming Surgical History, Satisfaction, and Unmet Needs Among Transgender Adults

Posted September 16, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32494?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091825

Orbitofrontal Gray-White Interface Injury and the Association of Soccer Heading With Verbal Learning

Posted September 16, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32461?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091825

Prescriptions of Essentially Placebo Treatments Among General Practitioners in 21 Countries

Posted September 16, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32672?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091825

Prostate-Specific Antigen Levels Among Participants Receiving Annual Testing

Posted September 16, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.3386?guestAccessKey=6dc30422-e619-46fc-81a9-364390150fac&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091825

Revised Diagnostic Criteria for Vascular Cognitive Impairment and Dementia—The VasCog-2-WSO Criteria

Posted September 15, 2025 by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 3:50 A.M. (ET), TUESDAY, SEPTEMBER 16, 2025

Media advisory: The full and editorial are linked to this news release. This study is being presented at VasCog 2025.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2025.3242?guestAccessKey=268765e4-5334-4be1-8246-c568cb37cb9c&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091625

About The Study: The International Society for Vascular Behavioural and Cognitive Disorders (VasCog)-2- World Stroke Organization (WSO) criteria update the VasCog criteria for the diagnosis of vascular cognitive impairment and dementia (VCID), providing operationalization and additional guidance on potential neuroimaging and fluid biomarkers. VasCog-2-WSO should provide an international standard for VCID diagnosis, facilitating diagnostic consistency among clinicians and researchers.

Corresponding Authors: To contact the corresponding authors, email Perminder S. Sachdev, MD, PhD, MBBS (p.sachdev@unsw.edu.au) and Adam C. Bentvelzen, PhD, MClinNeuroPsych (a.bentvelzen@unsw.edu.au).

(doi:10.1001/jamaneurol.2025.3242)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists

Posted September 15, 2025 by Jim Michalski

JAMA Surgery

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, SEPTEMBER 17, 2025

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2025.3590?guestAccessKey=f92dccf3-f8e2-4789-95d7-61dd539ed7e0&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091725

About The Study: The findings of this study suggest that metabolic bariatric surgery was associated with more weight loss at lower ongoing costs compared with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in class II and III obesity. Further study is needed to determine if metabolic bariatric surgery should still be considered the last resort in treating obesity.

Corresponding Author: To contact the corresponding author, George M. Eid, MD, email george.eid@ahn.org.

(doi:10.1001/jamasurg.2025.3590)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Nicotinamide for Skin Cancer Chemoprevention

Posted September 15, 2025 by Jim Michalski

JAMA Dermatology

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, SEPTEMBER 17, 2025

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2025.3238?guestAccessKey=6520c243-177a-4976-8bf1-e5ba93619fe4&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091725

About The Study: The results of this cohort study suggest that there is a decreased risk of skin cancer among patients treated with nicotinamide, with the greatest effect seen when initiated after the first skin cancer. Nicotinamide is a vitamin B3 derivative that is sold as an over-the-counter medication. JAMA Dermatology Editor in Chief Kanade Shinkai, MD, PhD, selected the paper as a highlight for journalists. Once published, the paper will be accompanied by a podcast and short video.

Corresponding Author: To contact the corresponding author, Lee Wheless, MD, PhD, email lee.e.wheless@vumc.org.

(doi:10.1001/jamadermatol.2025.3238)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Integrated Behavioral Health Services and Psychosocial Symptoms in Children

Posted September 12, 2025 by Alexandra Marusarz

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, SEPTEMBER 16, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32020?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091625

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of children at federally qualified health centers implementing behavioral health integration, receipt of encounters with behavioral health clinicians and psychotropic prescriptions were associated with improved psychosocial symptoms, suggesting that expanding integrated pediatric behavioral health care might enhance behavioral health outcomes among marginalized pediatric populations.

Corresponding author: To contact the corresponding author, R. Christopher Sheldrick, Ph.D., email radley.sheldrick@umassmed.edu.

(doi: 10.1001/jamanetworkopen.2025.32020)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Disparities in Utilization of Uterine Fibroid Embolization

Posted September 12, 2025 by Alexandra Marusarz

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, SEPTEMBER 16, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32100?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091625

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cross-sectional study, uterine fibroid embolization was underutilized with significant disparities across socioeconomic factors. Further efforts are needed to equitably expand access to uterine fibroid embolization across the country.

Corresponding author: To contact the corresponding author, Tarig S. Elhakim, M.D., M.P.H., email tarigelhakim@gmail.com.

(doi: 10.1001/jamanetworkopen.2025.32100)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Remote Access to Urinary Incontinence Treatments for Women Veterans

Posted September 12, 2025 by Alexandra Marusarz

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32111?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091625

PREVENT and PCE Models for Estimating ASCVD Risk Stratified by Statin Exposure

Posted September 12, 2025 by Alexandra Marusarz

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32164?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091625

Survival by Treatment Recommendation and Receipt in Early-Stage Cervical Cancer

Posted September 12, 2025 by Alexandra Marusarz

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32206?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=091625

Donor-Derived Epstein-Barr Virus Infection Among Pediatric Kidney Transplant Recipients

Posted September 12, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.14067?guestAccessKey=e9c0224d-e810-489f-bdb2-ca0a421d0ca6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091725

Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes

Posted September 11, 2025 by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, SEPTEMBER 15, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2025.3243?guestAccessKey=5984867c-844f-4c44-83ca-3837692ff37e&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091525

About The Study: In this systematic review and meta-analysis of 18 trials, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly improved glycemic, weight, and cardiometabolic outcomes in children and adolescents with type 2 diabetes or obesity. Available data over a relatively short follow-up suggested suicidal ideation or behaviors were not significantly different, although gastrointestinal adverse effects warrant attention in long-term management.

Corresponding Author: To contact the corresponding author, Jingchuan Guo, MD, PhD, email guoj1@ufl.edu.

(doi:10.1001/jamapediatrics.2025.3243)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Global Trends and Disparities in Social Isolation

Posted September 11, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, SEPTEMBER 15, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32008?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091525

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cross-sectional study, social isolation was found to have increased globally after the COVID-19 pandemic, with the initial increase disproportionately seen in lower-income populations and subsequent increases broadening across socioeconomic strata. Targeted interventions for vulnerable groups and research examining country-level policies are urgently needed to mitigate high isolation levels and reduce inequities.

Corresponding Author: To contact the corresponding author, Thomas E. Fuller-Rowell, PhD, email tef0005@auburn.edu.

(doi:10.1001/jamanetworkopen.2025.32008)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Country of Birth, Race, Ethnicity, and Prenatal Depression

Posted September 11, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, SEPTEMBER 15, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.31844?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091525

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: Across racial and ethnic groups, prenatal depression diagnosis and moderate to severe depression symptoms varied by maternal nativity in this cross-sectional study. The observed advantage among non–U.S.-born individuals across other maternal and neonatal outcomes may not uniformly apply to prenatal mental health conditions when race and ethnicity are considered. Future research should explore sociocultural factors that may influence this association.

Corresponding Author: To contact the corresponding author, Kendria Kelly-Taylor, PhD, MPH, email kendria.d.kelly-taylor@kp.org.

(doi:10.1001/jamanetworkopen.2025.31844)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Home Training for Cerebellar Ataxias

Posted September 11, 2025 by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 5:30 P.M. (ET), SUNDAY, SEPTEMBER 14, 2025

Media advisory: The full study is linked to this news release. This study is being presented as a poster during the annual meeting of the American Neurological Association.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2025.3421?guestAccessKey=cd0dc69d-b2f5-401b-9e74-965c42d8a6e4&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091425

About The Study: In this randomized clinical trial, home high-intensity aerobic training improved ataxia symptoms, fatigue, and aerobic fitness more than dose-matched home balance training among individuals with cerebellar ataxias, a heterogenous group of disorders characterized by progressive disability due to loss of coordination. Individuals in the aerobic group who continued to train regularly maintained benefits at 1 year.

Corresponding Author: To contact the corresponding author, Scott Barbuto, MD, PhD, email sb3779@cumc.columbia.edu.

(doi:10.1001/jamaneurol.2025.3421)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Trends in Circumcision Among Newborn Males in the US

Posted September 11, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2025.2464?guestAccessKey=c95e169d-085b-4914-91ab-28a05867c25a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091525

Five-Year Outcomes from Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson Disease

Posted September 11, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2025.3373?guestAccessKey=244a8183-1d8b-4a6a-824f-530846e8a207&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091525

Over-the-Counter Retail Naloxone Sales

Posted September 11, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2025.4590?guestAccessKey=580df548-04f9-4b43-a229-8ac191067a6e&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091525

Menopausal Hormone Therapy and Cardiovascular Diseases in Women With Vasomotor Symptoms

Posted September 11, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2025.4510?guestAccessKey=20383ad3-b919-4b1b-bdc2-302a46686722&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091525

Parental Diseases of Despair and Suicidal Events in Their Children

Posted September 10, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, SEPTEMBER 12, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.31442?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091225

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This cohort study found an association of parental diseases of despair (defined as a suicide attempt, alcohol-related disease, or substance use disorder) with youth suicidal events; this finding may be underlying the increase in adolescent suicidal behavior observed in the U.S. over the past 2 decades. Improved access to care for parents with diseases of despair and systematic screening and referral of their offspring could help to reduce the adolescent suicide rate.

Corresponding Author: To contact the corresponding author, David A. Brent, MD, email brentda@upmc.edu.

(doi:10.1001/jamanetworkopen.2025.31442)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Childhood Loneliness and Cognitive Decline and Dementia Risk in Middle-Aged and Older Adults

Posted September 10, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, SEPTEMBER 12, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.31493?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091225

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study, childhood loneliness was associated with cognitive decline and dementia risk in middle and later adulthood, even in the absence of adult loneliness. Early interventions aimed at reducing childhood loneliness may help promote lifelong cognitive health and reducing dementia risk.

Corresponding Author: To contact the corresponding author, Xiuhua Guo, PhD, email statguo@ccmu.edu.cn.

(doi:10.1001/jamanetworkopen.2025.31493)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Acupuncture for Chronic Low Back Pain in Older Adults

Posted September 10, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, SEPTEMBER 12, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.31348?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091225

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: The findings of this randomized clinical trial of older adults with chronic low back pain suggest that acupuncture needling provided greater improvements in back pain–related disability at 6 months and at 12 months compared with usual medical care alone. These findings support acupuncture needling as an effective and safe treatment option for older adults with chronic low back pain.

Corresponding Author: To contact the corresponding author, Lynn L. DeBar, PhD, MPH, email lynn.debar@kpchr.org.

(doi:10.1001/jamanetworkopen.2025.31348)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Modifiable Parental Factors and Adolescent Sleep During Early Adolescence

Posted September 9, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, SEPTEMBER 11, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.31333?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091125

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this prospective study of the Adolescent Brain Cognitive Development (ABCD) Study cohort, modifiable parental factors in early adolescence were associated with specific adolescent sleep outcomes 4 years later, with screen use and emotional regulation serving as mediators. Adolescent sex moderated the association between parental warmth and sleep chronotype. These findings highlight potential targets for evidence-based interventions to improve adolescent sleep health.

Corresponding Authors: To contact the corresponding authors, email Rosalind Ge, MSc (saig@student.unimelb.edu.au) and Vanessa Cropley, PhD (vcropley@unimelb.edu.au).

(doi:10.1001/jamanetworkopen.2025.31333)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Excess HIV Infections and Costs Associated With Reductions in HIV Prevention Services in the US

Posted September 9, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, SEPTEMBER 11, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.31341?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091125

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this economic evaluation estimating effects of the possible health care policy changes on HIV transmission, findings suggest that even modest reductions in pre-exposure prophylaxis (PrEP) coverage would result in thousands of avoidable HIV infections and billions of dollars of increases in net health care costs.

Corresponding Author: To contact the corresponding author, Patrick S. Sullivan, DVM, PhD, email pssulli@emory.edu.

(doi:10.1001/jamanetworkopen.2025.31341)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Race, Ethnicity, Insurance Payer, and Pediatric Cardiac Arrest Survival

Posted September 8, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, SEPTEMBER 10, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.31213?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091025

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this retrospective cohort study of pediatric in-hospital cardiac arrest in a large, national, administrative dataset, children of racial and ethnic minority groups receiving cardiopulmonary resuscitation (CPR) had higher odds of in-hospital mortality. In addition, the odds of in-hospital mortality among children receiving CPR were higher at hospitals with the highest proportion of Black patients.

Corresponding Author: To contact the corresponding author, Amanda J. O’Halloran, MD, MSHP, email ohallorana@chop.edu.

(doi:10.1001/jamanetworkopen.2025.31213)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

High-Intensity Exercise and Hippocampal Integrity in Adults With Cannabis Use Disorder

Posted September 8, 2025 by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, SEPTEMBER 10, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2025.2319?guestAccessKey=fda1fbaf-50da-4994-b2e9-3c996f8c47e3&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091025

About The Study: This trial found that a 12-week high-intensity interval training intervention did not improve hippocampal integrity or associated cognitive or mental health impairments while people continued to consume cannabis. However, results indicated that people with cannabis use disorder can engage in regular physical exercise programs and highlighted exercise as a potential strategy to reduce cannabis craving.

Corresponding Author: To contact the corresponding author, Murat Yücel, PhD, email murat.yucel@qimrb.edu.au.

(10.1001/jamapsychiatry.2025.2319)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis

Posted September 5, 2025 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11:00 A.M. ET, WEDNESDAY, SEPTEMBER 10, 2025

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.13722?guestAccessKey=0729b60f-de2c-4d85-8b75-a378b02fc731&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=091025

About The Study: In men with suspected prostate cancer, provided image quality is adequate, an abbreviated biparametric magnetic resonance imaging (MRI) scan, with or without targeted biopsy, could become the new standard of care for prostate cancer diagnosis. With approximately 4 million prostate MRIs performed globally annually, adopting biparametric MRI could substantially increase scanner throughput and reduce costs worldwide.

Corresponding Author: To contact the corresponding author, Veeru Kasivisvanathan, PhD, email veeru.kasi@ucl.ac.uk.

(doi:10.1001/jama.2025.13722)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Long COVID and Food Insecurity in US Adults, 2022-2023

Posted September 5, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, SEPTEMBER 9, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.30730?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090925

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: The findings of this study suggest that
food insecurity may be an important and modifiable risk factor for long COVID and that strengthening access to
programs like Supplemental Nutrition Assistance Program (SNAP), raising awareness, and simplifying enrollment could help reduce the health burden of long COVID.

Corresponding Author: To contact the corresponding author, Jaya Aysola, MD, MPH, email jaysola@upenn.edu.

(doi:10.1001/jamanetworkopen.2025.30730)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Bariatric Surgery and Incident Development of Obesity-Related Comorbidities

Posted September 5, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, SEPTEMBER 9, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.30787?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090925

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study, bariatric surgery was associated with a significantly lower risk of developing major metabolic comorbidities compared with the medical weight management program. This finding supports the relevance of bariatric surgery as a durable approach for obesity-related risk mitigation.

Corresponding Author: To contact the corresponding author, Amanda L. Bader, MD, email amanda.bader@pennmedicine.upenn.edu.

(doi:10.1001/jamanetworkopen.2025.30787)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

High Blood Pressure in Childhood and Premature Cardiovascular Disease Mortality

Posted September 4, 2025 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 10:00 A.M. ET, SUNDAY, SEPTEMBER 7, 2025

Media advisory: This study is being presented at the AHA Hypertension Scientific Sessions 2025. The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.14405?guestAccessKey=9084f39a-f4d2-4b96-82f5-8f38e70c60f0&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090725

About The Study: In a large sample of U.S. children born between 1959 and 1966, higher blood pressure (BP) at age 7 was associated with greater risk of premature cardiovascular disease (CVD) mortality. These findings build upon prior research that linked childhood systolic BP with fatal CVD in young adulthood, but that sample had a follow-up duration through a mean age of only 46 years. This study extends that work with follow-up into the mid-50s and demonstrated consistency in the magnitude of the associations within siblings, which mitigates concerns regarding unmeasured confounding due to shared family or lifestyle characteristics.

Corresponding Author: To contact the corresponding author, Alexa A. Freedman, PhD, email alexa.freedman@northwestern.edu.

(doi:10.1001/jama.2025.14405)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome

Posted September 4, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.13668?guestAccessKey=ba4458a2-7a79-41be-ab38-d3c947aa2b2f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090825

Ambient Air Pollution and the Severity of Alzheimer Disease Neuropathology

Posted September 4, 2025 by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, SEPTEMBER 8, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2025.3316?guestAccessKey=55b8956b-ab3e-4a8e-a029-d503e36f33ed&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090825

About The Study: In this study, fine particulate matter air pollution exposure was associated with increased dementia severity and increased Alzheimer disease neuropathologic change. Population-based studies are needed to better understand this relationship.

Corresponding Author: To contact the corresponding author, Edward B. Lee, MD, PhD, email edward.lee@pennmedicine.upenn.edu.

(doi:10.1001/jamaneurol.2025.3316)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes

Posted September 4, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, SEPTEMBER 8, 2025

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.30952?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090825

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this cohort study of patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) use was associated with body mass index (BMI) -dependent cardiovascular benefits and consistent kidney protection, suggesting the importance of BMI stratification in guiding treatment decisions.

Corresponding Author: To contact the corresponding author, Ming-Lung Tsai, MD, email mltsai.cgmh@gmail.com.

(doi:10.1001/jamanetworkopen.2025.30952)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Pre-Dialysis Nephrology Care Disparities and Incident Vascular Access Among Hispanic Individuals

Posted September 3, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, SEPTEMBER 5, 2025

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.30972?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090525

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This retrospective cohort study of incident hemodialysis patients found that system-based disparities in pre-dialysis access to nephrology care contribute to approximately one-third of incident vascular access disparities among Hispanic individuals. Targeted system-based remedies and policies are needed to improve timely identification and nephrology referrals among Hispanic individuals, for equitable improvements in incident kidney failure outcomes.

Corresponding Author: To contact the corresponding author, Ashutosh M. Shukla, MBBS, MD, email ashushukla@hotmail.com.

(doi:10.1001/jamanetworkopen.2025.30972)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

New and Recurring Food Insecurity During and After the COVID-19 Pandemic

Posted September 3, 2025 by Jim Michalski

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, SEPTEMBER 5, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2025.3603?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=090525

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

About The Study: In this survey study examining food insecurity in the U.S. during and after the COVID-19 pandemic, food insecurity declined among all subgroups between 2019 and 2021 but exceeded pre-pandemic levels by 2023; new food insecurity accounted for much of that increase. The increase in new food insecurity is concerning, as these households face elevated risk for adverse health outcomes.

Corresponding Author: To contact the corresponding author, Elise Sheinberg, MPH, RDN, email esheinberg@g.harvard.edu.

(doi:10.1001/jamahealthforum.2025.3603)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Food Insecurity and Rural Child and Family Functioning

Posted September 3, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, SEPTEMBER 5, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.30691?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090525

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: The findings of this study suggest that caregiver stress and household instability may be key mechanisms by which food insecurity is negatively associated with child mental health.

Corresponding Author: To contact the corresponding author, Merelise R. Ametti, PhD, MPH, email merelise.ametti@mainehealth.org.

(doi:10.1001/jamanetworkopen.2025.30691)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Telephone vs Text Message Counseling and Physical Activity Among Midlife and Older Adults

Posted September 2, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, SEPTEMBER 4, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.28858?guestAccessKey=1b34668e-afe8-4888-aa3d-dd05b3b83eff&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090425

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this study of short message service (SMS) vs human phone advising, a customizable SMS system produced significant 12-month walking increases for aging Latino/a adults comparable to the significant improvements attained by participants in the human advisors group. These results provide support for such mobile health platforms, which can expand program choices for broader segments of the population.

Corresponding Author: To contact the corresponding author, Abby C. King, PhD, email king@stanford.edu.

(doi:10.1001/jamanetworkopen.2025.28858)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Studies Being Presented at the 10th International Congress on Peer Review and Biomedical Publication

Posted September 2, 2025 by Jim Michalski

JAMA and JAMA Network Open

EMBARGOED FOR RELEASE: 9 A.M. ET, WEDNESDAY, SEPTEMBER 3, 2025

Media advisory: The full studies and commentary are linked to this news release. These studies are being presented at the 10^th International Congress on Peer Review and Biomedical Publication. For more information on the Congress, go to peerreviewcongress.org.

JAMA

Transparent Reporting of Observational Studies Emulating a Target Trial—The TARGET Statement

About The Study: Application of the Transparent Reporting of Observational Studies Emulating a Target Trial (TARGET) guideline recommendations aims to improve reporting transparency and peer review and help researchers, clinicians, and other readers interpret and apply the results.

Corresponding Author: To contact the corresponding author, James H. McAuley, PhD, email james.mcauley@unsw.edu.au.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.13350?guestAccessKey=6ad54c92-efdb-4815-8df4-2ed119c048a7&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090325

# # #

JAMA Network Open

Nonregistration, Discontinuation, and Nonpublication of Randomized Trials

About The Study: Findings from this systematic review indicated that nonregistration, premature discontinuation due to poor recruitment, and nonpublication of randomized clinical trial (RCT) results remained major challenges, especially for non–industry-sponsored trials. To mitigate these challenges, requirements enforced by funders and ethics committees also taking into account legal obligations should be considered and empirically evaluated.

Corresponding Author: To contact the corresponding author, Matthias Briel, MD, PhD, email matthias.briel@usb.ch.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.24440?guestAccessKey=d272dd36-3307-4ccd-88be-0d8095689054&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090325

# # #

JAMA Network Open

Improving the Reporting on Health Equity in Observational Research (STROBE-Equity)

About The Study: Use of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) -Equity extension alongside the STROBE statement when writing up completed reports of observational studies has the potential to advance the reporting of health equity data and considerations. Improved reporting of this information may help knowledge users better identify and apply evidence relevant to populations experiencing inequities.

Corresponding Author: To contact the corresponding author, Omar Dewidar, MSc, email Odewi090@uottawa.ca.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.32512?guestAccessKey=7f083c14-4bf5-4544-a804-54ca0dd5323c&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090325

# # #

Editor’s Note: Please see the articles for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder

Posted September 2, 2025 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11:00 A.M. ET, THURSDAY, SEPTEMBER 4, 2025

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.13481?guestAccessKey=f420494d-a51d-442c-9d7c-4d14dbbe1aae&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090425

About The Study: In participants with moderate to severe generalized anxiety disorder, a single dose of MM120 (lysergide D-tartrate) produced a dose-dependent reduction in anxiety. Lysergide, or lysergic acid diethylamide (LSD), is a semisynthetic psychedelic drug. An oral pharmaceutical formulation of LSD is MM120. These results support the dose-dependent efficacy of MM120 and inform the dose selection for phase 3 pivotal trials.

Corresponding Author: To contact the corresponding author, Daniel R. Karlin, MD, MA, email medaffairs@mindmed.co.

(doi:10.1001/jama.2025.13481)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease

Posted August 29, 2025 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11:45 A.M. ET, SUNDAY, AUGUST 31, 2025

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025. The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.16189?guestAccessKey=be63c976-6538-49b1-86a8-09d9ea6853b8&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083125

About The Study: Fractional flow reserve-guided complete revascularization during the index procedure resulted in a significant reduction in the composite of all-cause death, nonfatal myocardial infarction, any revascularization, and stroke at 1 year. This was mainly driven by reduced repeat revascularization.

Corresponding Author: To contact the corresponding author, Tobias F. S. Pustjens, MD, email t.pustjens@gmail.com.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function

Posted August 29, 2025 by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 8:30 A.M. ET, MONDAY, SEPTEMBER 1, 2025

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025. The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.3393?guestAccessKey=0e6929b9-90af-492b-991f-52f316b6dfb9&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090125

About The Study: In this secondary analysis of the AZALEA-TIMI 71 randomized clinical trial, abelacimab consistently reduced the risk of bleeding relative to rivaroxaban irrespective of kidney function. These findings suggest that abelacimab may offer a particularly favorable safety profile among those with chronic kidney disease; however, larger studies are necessary to characterize the efficacy of abelacimab for stroke prevention in atrial fibrillation.

Corresponding Author: To contact the corresponding author, Siddharth M. Patel, MD, MPH, email spatel@bwh.harvard.edu.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Helicobacter pylori Screening After Acute Myocardial Infarction

Posted August 28, 2025 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 2:35 A.M. ET, MONDAY, SEPTEMBER 1, 2025

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025. The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.15047?guestAccessKey=1d1e7c37-6529-4373-a11a-e0fa1bc46853&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090125

About The Study: Among unselected patients with acute myocardial infarction, routine H pylori screening did not significantly reduce the risk of upper gastrointestinal bleeding.

Corresponding Author: To contact the corresponding author, Robin Hofmann, MD, PhD, email robin.hofmann@ki.se.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Participation of Women in Cardiovascular Trials From 2017 to 2023

Posted August 28, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 4:55 A.M. ET, SUNDAY, AUGUST 31, 2025

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025. The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.29104?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=083125

About The Study: The findings of this study highlight both progress and persistent challenges in representation of women within cardiovascular trials. These gaps not only limit the generalizability of trial outcomes but also perpetuate inequities in evidence-based care for women with cardiovascular conditions.

Corresponding Author: To contact the corresponding author, Martha Gulati, MD, MS, email martha.gulati@csmc.edu.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation

Posted August 28, 2025 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11:30 A.M. ET, SUNDAY, AUGUST 31, 2025

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025. The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.14679?guestAccessKey=3d97c611-aa9b-4680-b726-db495a67c47b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083125

About The Study: Among patients without documented atrial arrhythmia recurrence after catheter ablation for atrial fibrillation, discontinuing oral anticoagulant therapy resulted in a lower risk for the composite outcome of stroke, systemic embolism, and major bleeding vs continuing direct oral anticoagulant therapy.

Corresponding Author: To contact the corresponding author, Boyoung Joung, MD, email cby6908@yuhs.ac.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction

Posted August 28, 2025 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 3:30 A.M. ET, SUNDAY, AUGUST 31, 2025

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025. The full study is linked to this news release. Please note, the PDF has the incorrect embargo time. The correct embargo time is 3:30 A.M. ET.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.14092?guestAccessKey=604055a2-ce86-4984-8c53-11e9184281a1&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083125

About The Study: In patients with cardiometabolic heart failure with preserved ejection fraction, semaglutide and tirzepatide showed more than 40% risk reduction for the composite of hospitalization for heart failure or all-cause mortality compared with a placebo proxy. Tirzepatide showed no meaningful benefit over semaglutide.

Corresponding Author: To contact the corresponding author, Nils Krüger, MD, email nkruger1@bwh.harvard.edu.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk

Posted August 28, 2025 by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 11:30 A.M. ET, SATURDAY, AUGUST 30, 2025

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025. The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.3403?guestAccessKey=6f1c3c46-c58f-4fd4-a450-f7b2ec3aabdd&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083025

About The Study: In this individual participant data meta-analysis of 4 randomized clinical trials (RCTs), and an overall meta-analysis of 8 RCTs of patients with severe symptomatic aortic stenosis at low to intermediate risk, transcatheter aortic valve implantation (TAVI) was associated with a reduction in the 1-year incidence of all-cause death or any stroke. These findings emphasize TAVI as alternative option in patients at low to intermediate risk. Long-term follow-up is warranted to evaluate sustainability of these findings.

Corresponding Authors: To contact the corresponding authors, email Moritz Seiffert, MD, (moritz.seiffert@bergmannsheil.de) and Andreas Ziegler, PhD, (andreas.ziegler@cardio-care.ch).

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis

Posted August 28, 2025 by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 8:15 A.M. ET, SATURDAY, AUGUST 30, 2025

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025. The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.3369?guestAccessKey=104b6fb6-4ae2-4323-878a-fcdb18f056a8&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083025

About The Study: In this study, clonal hematopoiesis of indeterminate potential (CHIP) was a strong risk factor for myocarditis and pericarditis among middle-aged adults. Targeting CHIP and its downstream pathways may represent a strategy for preventing or treating pericarditis and myocarditis.

Corresponding Author: To contact the corresponding author, Michael C. Honigberg, MD, MPP, email mhonigberg@mgh.harvard.edu.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults

Posted August 28, 2025 by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 8 A.M. ET, SATURDAY, AUGUST 30, 2025

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025. The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.3460?guestAccessKey=0a4638e8-3454-4dbd-b770-dcb4ec996b42&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083025

About The Study: This study found reduced incidence of cardiorespiratory hospitalization among those who received high-dose inactivated influenza vaccine vs standard-dose inactivated influenza vaccine, driven by a lower incidence of cardiovascular hospitalizations, and particularly heart failure hospitalizations. These differences should be interpreted as exploratory findings in the setting of a large randomized clinical trial with a neutral primary outcome.

Corresponding Author: To contact the corresponding author, Tor Biering-Sørensen, MD, MSc, MPH, PhD, email tor.biering@gmail.com.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region

Posted August 28, 2025 by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 5:15 A.M. ET, SATURDAY, AUGUST 30, 2025

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025. The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.3377?guestAccessKey=a3e73f9e-d8c7-4a39-a52c-252ce31b4740&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083025

About The Study: This situational analysis of cross-sectional WHO STEPS surveys of cardiovascular health (CVH) status region identified actionable factors of the CVH status across 22 countries in the WHO African Region. This information is crucial for guiding policy efforts in cardiovascular disease prevention in countries of the WHO African Region.

Corresponding Author: To contact the corresponding author, Jean-Philippe Empana, MD, PhD, email jean-philippe.empana@inserm.fr.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock

Posted August 28, 2025 by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 5 A.M. ET, SATURDAY, AUGUST 30, 2025

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025. The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.3337?guestAccessKey=7d97951f-1028-4d1f-9e0b-68f756fb4d9e&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083025

About The Study: Randomization systolic blood pressure (SBP) was associated with the survival benefit of microaxial flow pump treatment, with the most hypotensive patients deriving the largest survival benefit. Early SBP may help identify patients most likely to gain a net benefit from microaxial flow pump treatment. Findings are hypothesis generating.

Corresponding Author: To contact the corresponding author, Astrid Duus Mikkelsen, MD, email astrid.duus.mikkelsen@reigonh.dk.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine

Posted August 28, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 8 A.M. ET, SATURDAY, AUGUST 30, 2025

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025. The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.36889?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=083025

About The Study: In this prespecified analysis of the DANFLU-2 trial, the risk of incident myocarditis or pericarditis was lower among individuals randomized to high-dose inactivated influenza vaccine vs standard-dose- inactivated influenza vaccine. Despite sporadic reports of myocarditis and pericarditis associated with influenza vaccination, the consistency of our results with vs without inclusion of events occurring immediately after vaccination negates a dose-response association and a causal link.

Corresponding Author: To contact the corresponding author, Tor Biering-Sørensen, MD, MSc, MPH, PhD, email tor.biering@gmail.com.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults

Posted August 28, 2025 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 8:15 A.M. ET, SATURDAY, AUGUST 30, 2025

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025. The full study and related article are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.15405?guestAccessKey=c6db40fb-eda4-4735-b83a-ee7345ff263d&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083025

About The Study: In adults age 60 or older, all-cause cardiorespiratory hospitalization was significantly lower with respiratory syncytial virus (RSV) prefusion F protein than with no vaccine. The findings suggest potential downstream cardiorespiratory benefits of RSV immunization, although the effect on all-cause cardiovascular hospitalization was not statistically significant.

Corresponding Author: To contact the corresponding author, Tor Biering-Sørensen, MD, MSc, MPH, PhD, email tor.biering@gmail.com.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction

Posted August 28, 2025 by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 8:45 A.M. ET, FRIDAY, AUGUST 29, 2025

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025. The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.3099?guestAccessKey=9e804d62-62ee-4911-96b8-b07c100d4c75&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082925

About The Study: In patients 75 years or older with myocardial infarction and multivessel disease, the benefit of physiology-guided complete revascularization over culprit-lesion–only treatment was sustained at 3 years.

Corresponding Author: To contact the corresponding author, Simone Biscaglia, MD, email bscsmn@unife.it.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Remote Screening for Asymptomatic Atrial Fibrillation

Posted August 28, 2025 by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 5:15 A.M. ET, FRIDAY, AUGUST 29, 2025

Media advisory: This study is being presented at the European Society of Cardiology Congress 2025. The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.15440?guestAccessKey=19401952-2e93-4066-a5e1-ee23e2bb40fe&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082925

About The Study: In this remote randomized clinical trial, mail-based atrial fibrillation (AF) screening with an electrocardiogram patch in older patients at moderate to high risk of stroke led to a modest long-term increase in AF diagnosis at 2.5 years.

Corresponding Authors: To contact the corresponding authors, email Rohan Wijesurendra, DPhil, rohan.wijesurendra@ndph.ox.ac.uk and Barbara Casadei, DPhil, b.casadei@imperial.ac.uk.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Out-of-Hospital Cardiac Arrest in US Airports

Posted August 27, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.29754?guestAccessKey=b8181dd4-c32e-4478-9319-8b8cfe844961&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082925

Extreme Heat and Calls to Law Enforcement Related to Domestic Violence

Posted August 27, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.30530?guestAccessKey=5a587569-f9b8-49db-b075-2aa5fb634479&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082925

Adolescent Treatment Landscape of Depression, Suicidality, and Substance Use Disorder in the US

Posted August 27, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2025.2647?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082925

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

ADHD Diagnosis and Timing of Medication Initiation Among Children Ages 3 to 5

Posted August 27, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, AUGUST 29, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.29610?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082925

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this retrospective cohort study of preschool-age children with attention-deficit/hyperactivity disorder (ADHD) seen in primary care in 8 large pediatric health systems, many children were prescribed medications at or shortly after the first documented diagnosis. Analysis of clinical documentation is needed to understand early prescription patterns.

Corresponding Author: To contact the corresponding author, Yair Bannett, MD, MS, email ybannett@stanford.edu.

(doi:10.1001/jamanetworkopen.2025.29610)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Food Insecurity Prevalence Among US Medical Students

Posted August 27, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, AUGUST 29, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.29926?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082925

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: In this survey study, more than 1 in 5 U.S. medical students reported food insecurity, nearly double the level of U.S. households. These findings call for institutional and policy interventions to address medical students’ basic needs, ensuring the success of future physicians.

Corresponding Authors: To contact the corresponding authors, email Bassel M. Shanab, BA, (bassel.shanab@yale.edu) and Pavan Khosla, BA, (pavan.khosla@yale.edu).

(doi:10.1001/jamanetworkopen.2025.29926)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans

Posted August 27, 2025 by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, AUGUST 29, 2025

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.29842?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082925

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

About The Study: This analysis found a substantial expansion in coverage for injectable semaglutide, injectable tirzepatide, and oral semaglutide from 2020 to 2024, accompanied by a sharp rise in prior authorization requirements, from below 15% in 2023 Q3 to over 80% in 2024 Q3. Although coverage for these glucagon-like peptide-1 (GLP-1) receptor agonists remained consistently higher among Medicare Advantage Part Ds than standalone prescription drug plans, both plan types rapidly adopted prior authorization requirements beginning in late 2023.

Corresponding Author: To contact the corresponding author, Changchuan Jiang, MD, MPH, email changchuan.jiang@utsouthwestern.edu.

(doi:10.1001/jamanetworkopen.2025.29842)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

Contributing Factors to the Nonpublication of Head and Neck Cancer Clinical Trials

Posted August 26, 2025 by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/10.1001/jamaoto.2025.2549?guestAccessKey=dab3145a-b161-402d-83d6-bf1aa65e6249&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082825